Amgen To Buy TAVNEOS Developer ChemoCentryx In $3.7 Bln Cash Deal

Amgen (AMGN) Thursday said it has entered into a definitive agreement to acquire ChemoCentryx, Inc., (CCXI), a biopharmaceutical company, for $52 per share in cash, representing an enterprise value of around $3.7 billion.

In pre-market activity on Nasdaq, ChemoCentryx shares were gaining around 110 percent to trade at $50.62.

The transaction has been unanimously approved by each company's board of directors. The acquisition is subject to ChemoCentryx stockholder approval, regulatory approvals and other customary closing conditions.

The deal is expected to close in the fourth quarter of 2022.

ChemoCentryx is focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer

The acquisition includes TAVNEOS (avacopan), a first-in-class medicine for patients with serious autoimmune disease.

TAVNEOS is an orally administered selective complement component 5a receptor inhibitor. It was approved by the U.S. Food and Drug Administration in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), in combination with standard therapy.

U.S. sales of TAVNEOS in the first quarter of 2022, the first full quarter of sales, were $5.4 million. TAVNEOS is also approved in major markets outside the U.S., including the European Union and Japan.

In addition to TAVNEOS, ChemoCentryx has three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral checkpoint inhibitor for cancer.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Centers for Disease Control and Prevention or CDC director, Rochelle Walensky, has initiated a reorganization of the public health agency noting that it failed to reliably meet expectations during the coronavirus pandemic period, reports said. The proposed changes for a reset in the agency are expected to help it respond quicker to new health threats. While reporting financial results for the second quarter on Thursday, department store chain Kohl's Corp. (KSS) slashed its adjusted earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now projects adjusted earnings in a range of $2.80 to $3.20 per share on a net... Apple Inc. is planning to hold a launch event on September 7 to unveil its latest iPhone 14 line, Bloomberg reported citing people with knowledge of the matter. The tech major is also expected to roll out its latest version of three Apple Watch models including Series 8. The new products, which also include multiple new versions of Macs, and low and high-end iPads, are likely to reach stores...
Follow RTT